MCP1 Rat, Sf9
Sf9, Baculovirus cells
Small inducible cytokine A2, CCL2, Monocyte chemotactic protein 1, MCP-1, Monocyte chemoattractant protein 1, Monocyte chemotactic and activating factor, MCAF, Monocyte secretory protein JE, HC11, chemokine (C-C motif) ligand 2, MCP1, SCYA2, GDCF-2, SMC-CF, HSMCR30, MGC9434, GDCF-2 HC11
Sterile filtered colorless solution.
Greater than 90% as determined by SDS-PAGE.
Description
MCP1 Rat Recombinant produced in Sf9 Baculovirus cells is a single, glycosylated polypeptide chain containing 134 amino acids (24-148 aa) and having a molecular mass of 15.1kDa.
MCP1 is fused to a 6 amino acid His tag at C-terminus and purified by proprietary chromatographic techniques.
Product Specs
Chemokine (C-C motif) ligand 2 (CCL2), also called monocyte chemotactic protein-1 (MCP-1), is a small cytokine in the CC chemokine family. This protein has been identified at sites of tooth eruption and bone degradation and is expressed by mature osteoclasts in bone. CCL2 attracts immune cells like monocytes to areas of tissue damage or infection. The protein is initially synthesized as a precursor with a 23 amino acid signal peptide and a 76 amino acid mature peptide. Similar to other CC chemokines, the gene for CCL2 is located on chromosome 17 in humans. The cell surface receptors CCR2 and CCR5 bind CCL2.
Recombinant Rat MCP1 is produced in Sf9 Baculovirus cells. This glycosylated polypeptide chain consists of 134 amino acids (24-148 aa), has a molecular weight of 15.1 kDa, and includes a C-terminal 6-His tag. The protein is purified using proprietary chromatographic methods.
Sterile filtered, colorless solution.
The MCP1 Rat protein solution has a concentration of 0.5 mg/ml and contains 10% glycerol in Phosphate-Buffered Saline (pH 7.4).
For short-term storage (2-4 weeks), keep at 4°C. For extended storage, freeze at -20°C. The addition of a carrier protein (0.1% HSA or BSA) is advisable for long-term storage. Repeated freezing and thawing should be avoided.
Purity is greater than 90% as assessed by SDS-PAGE.
Small inducible cytokine A2, CCL2, Monocyte chemotactic protein 1, MCP-1, Monocyte chemoattractant protein 1, Monocyte chemotactic and activating factor, MCAF, Monocyte secretory protein JE, HC11, chemokine (C-C motif) ligand 2, MCP1, SCYA2, GDCF-2, SMC-CF, HSMCR30, MGC9434, GDCF-2 HC11
Sf9, Baculovirus cells
ADPQPDAVNA PLTCCYSFTG KMIPMSRLEN YKRITSSRCP KEAVVFVTKL KREICADPNK EWVQKYIRKL DQNQVRSETT VFYKIASTLR TSAPLNVNLT HKSEANASTL FSTTTSSTSV EVTSMTENHH HHHH
Product Science Overview
MCP-1 is a small protein with a molecular mass of approximately 14.1 kilodaltons and consists of 125 amino acids . It is characterized by its ability to attract monocytes and basophils, but not neutrophils or eosinophils . This chemotactic activity is essential for the body’s defense mechanisms, as it helps to recruit immune cells to sites where they are needed most, such as areas of infection or injury .
The recombinant form of MCP-1, specifically the rat version produced in Sf9 cells, is commonly used in research and industrial applications. The protein is typically expressed in Escherichia coli and purified using proprietary chromatographic techniques to achieve a purity level greater than 98% as determined by SDS-PAGE and HPLC analysis . The lyophilized protein is often provided without additives and may appear as a haze or film at the bottom of the vial .
MCP-1’s primary function is to act as a chemotactic factor, attracting monocytes to sites of inflammation. It binds to chemokine receptors CCR2 and CCR4, which are expressed on the surface of target cells . This binding triggers a cascade of intracellular signaling events that result in the directed migration of these cells towards higher concentrations of the chemokine .
MCP-1 has been implicated in the pathogenesis of several diseases characterized by monocytic infiltrates, such as psoriasis, rheumatoid arthritis, and atherosclerosis . Its role in these conditions makes it a potential target for therapeutic intervention. By modulating the activity or expression of MCP-1, it may be possible to develop treatments that reduce inflammation and improve patient outcomes in these diseases .
